The grant from the National Institutes of Health will allow researchers from the IU School of Medicine and the IU Luddy School of Informatics, Computing and Engineering to accelerate the search for new Alzheimer’s treatments.
Read More
Cancer specialists not involved in the new research expressed optimism that this may be a turning point in the quest for new options.
Read More
BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
The Crossroads Academic Medical Institute, or CAMI, will connect universities, health systems and clinical training sites.
Beta thalassemia major, also known as Cooley’s anemia and transfusion-dependent beta thalassemia, causes the body’s red blood cells to produce less hemoglobin than usual.
The Indianapolis-based drugmaker will partner with Profluent to develop and commercialize treatments for diseases with severe unmet needs.
Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley Children’s Health, has been working on a treatment for a neurodegenerative condition called Friedreich’s ataxia for decades.
The company has a goal to build a massive bank of bone marrow from deceased organ donors to treat patients with blood cancers and improve organ transplantations.
Through the collaboration, Telix and Regeneron expect to develop and commercialize next-generation radiopharmaceutical therapies targeting cancer.
Low founded seven companies based on intellectual property developed at Purdue, including Endocyte Inc., which he sold to Novartis Inc. in 2018 for $2.1 billion.
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
The goal of the National Science Foundation’s Engines program is to grow regional innovation ecosystems.
Indiana Gov. Mike Braun said the agreement “enables Elanco and its partners, including Purdue University, to accelerate the creation of an innovation district in downtown Indianapolis.”
Groups that filed the lawsuit to block the cuts said they represented “an unprecedented disruption to ongoing research” and threatened to undermine the NIH’s stature as a worldwide leader for diagnosing and treating illness.
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
Susan Orr and The grant will fund a new center at the medical school which will be one of only two in the U.S. dedicated to developing stem-cell-based models of the brain to better understand Alzheimer’s disease.
Health Secretary Robert F. Kennedy Jr. announced Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.
The new late-stage study will focus on people who are at risk of cognitive decline.
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
The Justice Department argued that a federal judge was wrong to block the National Institutes of Health from making cuts to align with President Donald Trump’s priorities.
The event, a partnership between the tissue bank and the city’s WNBA All-Star 2025 Host Committee, seeks 500 women to donate breast tissue for cancer research.
Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
